Scripps 36th Annual New Treatments In Chronic Liver Disease 2022 will delve into the latest liver therapy and transplantation drugs and therapies. We will carefully review trials and real-world data on oral medications for chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma, and end-stage liver disease complications like thrombocytopenia. New Treatments in Chronic Liver Disease gives doctors the newest liver disease treatment information. It concisely and comprehensively addresses several frequent issues.
Goals of Scripps 36th Annual New Treatments In Chronic Liver Disease 2022:
- Attending this live activity will allow participants to assess AASLD guidelines on viral, autoimmune, reproductive, and chronic liver disease.
- Learn about chronic liver disease vascular problems and coagulation treatment.
- Summarize the NAFLD (AGA), DILI, hemochromatosis (ACG), and non-invasive fibrosis indicators (EASL) criteria.
- Assessing PBC/PSC drug development.
- Treat and manage ascites and hepatorenal syndrome effectively.
Reviews
There are no reviews yet.